In addition, dabrafenib plus trametinib, compared with vemurafenib monotherapy, also significantly improved the overall survival in previously untreated patients with metastatic melanoma with BRAF V600E or V600K mutations and without increased overall toxicity [84]. This evidence concerns the gene BRAF and metastatic melanoma.